Citigroup upgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) from a sell rating to a neutral rating in a research report report published on Wednesday, Marketbeat Ratings reports. The brokerage currently has $18.00 price objective on the biotechnology company’s stock.

Several other research analysts have also issued reports on the stock. Canaccord Genuity reissued a buy rating on shares of Atara Biotherapeutics in a research note on Thursday, November 9th. Jefferies Group reissued a buy rating and set a $30.00 target price on shares of Atara Biotherapeutics in a research note on Thursday, October 5th. Goldman Sachs Group reissued a neutral rating and set a $20.00 target price on shares of Atara Biotherapeutics in a research note on Friday, October 6th. Finally, ValuEngine raised shares of Atara Biotherapeutics from a sell rating to a hold rating in a research note on Friday, December 29th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the stock. Atara Biotherapeutics has an average rating of Hold and an average target price of $26.00.

Shares of Atara Biotherapeutics (ATRA) traded up $0.50 during midday trading on Wednesday, reaching $18.50. 485,452 shares of the company traded hands, compared to its average volume of 799,034. The company has a market capitalization of $695.53, a price-to-earnings ratio of -5.33 and a beta of 1.27. Atara Biotherapeutics has a fifty-two week low of $11.80 and a fifty-two week high of $23.00.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by ($0.05). analysts predict that Atara Biotherapeutics will post -4 EPS for the current fiscal year.

In other Atara Biotherapeutics news, EVP Christopher Haqq sold 6,000 shares of the firm’s stock in a transaction on Monday, October 16th. The shares were sold at an average price of $14.35, for a total value of $86,100.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO John Mcgrath sold 32,000 shares of the firm’s stock in a transaction on Friday, December 29th. The shares were sold at an average price of $20.00, for a total transaction of $640,000.00. The disclosure for this sale can be found here. Insiders sold 128,388 shares of company stock worth $2,294,572 over the last ninety days. Insiders own 16.20% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. Schwab Charles Investment Management Inc. lifted its stake in shares of Atara Biotherapeutics by 16.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 92,974 shares of the biotechnology company’s stock valued at $1,302,000 after buying an additional 13,394 shares in the last quarter. Perceptive Advisors LLC bought a new position in shares of Atara Biotherapeutics in the third quarter valued at $581,000. Vanguard Group Inc. lifted its stake in shares of Atara Biotherapeutics by 1.7% in the second quarter. Vanguard Group Inc. now owns 845,877 shares of the biotechnology company’s stock valued at $11,842,000 after buying an additional 13,952 shares in the last quarter. Essex Investment Management Co. LLC bought a new position in shares of Atara Biotherapeutics in the third quarter valued at $429,000. Finally, Neuberger Berman Group LLC lifted its stake in shares of Atara Biotherapeutics by 15.2% in the third quarter. Neuberger Berman Group LLC now owns 1,115,041 shares of the biotechnology company’s stock valued at $18,454,000 after buying an additional 147,061 shares in the last quarter. 85.61% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/citigroup-upgrades-atara-biotherapeutics-atra-to-neutral/1797995.html.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.